Compounded GLP-1 Enforcement Tracker: FDA Warning Letters, Claim Types, and Safety Data

By The RX Index Editorial Team · The RX Index Research — independent pricing-intelligence and reference resource for the GLP-1 market

This is the compounded-GLP-1 enforcement tracker — a dated, primary-sourced record of how U.S. regulators are policing compounded GLP-1 weight-loss drugs. The cleanest number, current as of July 2, 2026: the FDA has issued at least 55 warning letters to telehealth companies in two 2026 waves over how they advertise compounded semaglutide and tirzepatide — 30 announced March 3 and 25 in June — on top of a broader wave of more than 50 letters to GLP-1 compounders and manufacturers in September 2025.

None of it lives in one place. The counts sit in FDA press releases. The row-level facts sit in dozens of individual letters. The safety totals sit on a drug-safety page. The legal deadlines sit on a compounding-policy page, and the court rulings sit on the federal docket. We pulled it together, dated it, coded it, and linked every piece back to the source.

The numbers, up front

Source: U.S. Food and Drug Administration press releases, warning letters, drug-safety pages, and compounding guidance; secondary confirmation from Wilson Sonsini, Sheppard Mullin, and Endpoints News. Compiled and verified by The RX Index on July 2, 2026.

What is the compounded-GLP-1 enforcement tracker?

It is a dated, source-linked record of public U.S. enforcement activity against compounded GLP-1 drugs — mostly FDA warning letters, coded by company, drug, date, and the type of claim the FDA flagged, plus the surrounding regulatory and court timeline. Its core finding is that the FDA’s 2026 campaign is aimed less at the act of compounding than at marketing: how telehealth companies describe compounded semaglutide, tirzepatide, and liraglutide to consumers.

How we built it: we read the FDA’s press releases and guidance, opened and read the individual warning letters we cite, pulled the shortage and enforcement deadlines from the FDA compounder-policy page, confirmed the litigation from the federal court record, and coded each letter against the FDA’s own list of prohibited claims. Fuller methodology is near the bottom. One caveat belongs right here: a warning letter is an allegation, not a finding of guilt. It sets out the FDA’s concerns and invites the company to respond. Several companies in this tracker may have since corrected the claims at issue.

How many FDA warning letters have targeted compounded GLP-1 marketing?

The FDA has run at least three public enforcement waves touching compounded GLP-1 promotion since September 2025. The two aimed specifically at telehealth companies are the cleanest to count: 30 letters announced March 3, 2026, and 25 letters in June 2026 — at least 55 telehealth letters in 2026 alone. The September 2025 wave was broader, hitting compounders, online sellers, and even the brand-name manufacturers.

Source: FDA press release (March 3, 2026); FDA warning-letter database; Wilson Sonsini, Sheppard Mullin, McDermott Will & Emery, and Endpoints News reporting. Verified by The RX Index, July 2, 2026.

Two details most summaries miss. First, the September 2025 count depends on how you slice it: the FDA sent more than 50 warning letters in that push, and it did not spare the brand-makers — Novo Nordisk and Eli Lilly each got a letter over their own promotional claims, the same week the compounders did. Second, that wave was broader than telehealth; the two 2026 waves are the ones aimed squarely at telehealth marketing.

In the March announcement, FDA Commissioner Marty Makary put the shift plainly — “It’s a new era” — and the agency said that over the prior six months it had sent thousands of letters telling pharmaceutical and telehealth firms to pull misleading ads, more than it had sent in the entire preceding decade.

The full enforcement timeline

Here is the whole story on one clock, from the 2022 shortages to the July 2026 comment deadline, each entry linked to its primary source. This is the part a writer can lift a single dated row from without rebuilding the chronology from scratch.

Source: FDA press releases, the FDA compounder-policy page, the Federal Register (Docket FDA-2018-N-3240), federal court records (N.D. Tex.), and legal-trade reporting (Foley & Lardner, Buchanan Ingersoll, McDermott, ArentFox Schiff, Wilson Sonsini, Endpoints News). Verified by The RX Index, July 2, 2026.

Which telehealth companies got FDA warning letters?

FDA warning letters name the company, the website reviewed, the compounded drugs offered, and the specific claims the agency considers false or misleading. The table below is the set of telehealth GLP-1 letters we have read in full and coded ourselves; we add rows as we verify them. The FDA’s warning-letter database is the authoritative complete index — search the term “telehealth,” which is exactly what the FDA itself tells people to do.

Claim-type codes (1–6) are defined in the next section. Each code maps to the FDA’s own list of prohibited marketing claims.

Source: individual FDA warning letters (fda.gov), each read and coded by The RX Index against the FDA’s own list of prohibited claims (defined in Table 5 below). Claim-type codes reflect our reading of each letter’s stated violations, not FDA’s own numbering. Verified July 2, 2026. For the complete set of telehealth GLP-1 letters, search “telehealth” in the FDA warning-letter database.

Reading the letters yourself turns up things a count can’t. The Hims letter, addressed to CEO Andrew Dudum, quotes just two website lines — “Same active ingredient as Ozempic and Wegovy” and “Clinically proven ingredients” — and the FDA’s conclusion is that they imply the product is the same as an FDA-approved drug. Join Josie’s and MEDVi’s letters object that the compounded vials carried the company’s own name on the label, which the FDA says implies the telehealth firm is the compounder when it isn’t. Momentum Health’s letter is the only June 2026 telehealth letter to name liraglutide, and flagged a claim that the product came from an “FDA-licensed compounding facility” — language the FDA calls false because it does not license compounding facilities.

What exactly is the FDA accusing these companies of?

The FDA’s guidance to telehealth companies lists five specific claim types it treats as false or misleading for compounded drugs, and the warning letters map onto that list. In plain terms: don’t imply the telehealth brand is the compounder, don’t call a compounded drug “generic” or “the same as” an approved one, don’t claim FDA approval or review, don’t claim it’s “clinically proven” to match the brand, and don’t call the pharmacy “FDA-approved” or “FDA-licensed.” A sixth, separate concern covers marketing ingredients like retatrutide that cannot be compounded at all.

Source: “FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs” and “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss,” both current as of June 15, 2026. Codes assigned by The RX Index.

Why a taxonomy instead of another recap? Once you know the five buckets, every new letter sorts itself, and you can measure which claim the FDA is leaning on. In the letters we coded, category 1 (equivalence) is universal, category 2 (implying FDA approval) is close behind, and the “FDA-licensed facility” claim (category 4) shows up as soon as a company tries to borrow the FDA’s credibility for its supply chain.

What does the FDA’s compounded GLP-1 safety data show?

As of May 31, 2026, the FDA reported 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency attaches two caveats in the same breath, and any honest use of these numbers has to carry them: an adverse-event report does not prove the drug caused the event, and the totals are almost certainly undercounts, because state-licensed pharmacies that are not outsourcing facilities are not federally required to report at all.

Source: FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss,” current as of June 15, 2026. Figures are cumulative reports to FDA, not confirmed causal events.

Because these numbers get quoted loosely, here is exactly what they do and do not measure — a caveat block you can cite instead of stripping the context off the headline figure.

Source: FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” (June 15, 2026). Framing by The RX Index.

What the FDA says is behind the reports: dosing errors, some serious enough to require hospitalization, often from patients drawing the wrong amount out of multidose vials; adverse events from doses beyond the approved label; and unapproved salt forms — semaglutide sodium and semaglutide acetate — which are different active ingredients than the approved drug, with no established equivalence and, in the FDA’s words, no lawful basis for use in compounding. The agency also notes it is aware of an adverse event tied to a compounded tirzepatide product whose label named a pharmacy that had not actually made it.

Are compounded semaglutide and tirzepatide still legal?

Broadly, no — not as regular copies of the approved drugs. As of July 2, 2026, the shortage-based enforcement discretion that once let pharmacies and outsourcing facilities make copies of semaglutide and tirzepatide has ended. A narrow exception survives: under section 503A, a pharmacy can still compound a patient-specific version when a prescriber documents a real clinical difference the approved drug cannot meet — an allergy to an inactive ingredient, say — but not for cost, convenience, or preference, and not at scale. The FDA calls the prohibited category compounding a drug that is “essentially a copy” of a commercially available product, made regularly or in inordinate amounts.

Two terms decide everything here. A 503A pharmacy compounds for an individual patient under a prescription, overseen by a state board of pharmacy. A 503B outsourcing facility is registered with the FDA, follows manufacturing-grade quality rules, and can make larger batches without patient-specific prescriptions. While a drug sits on the FDA shortage list, that status opens compounding pathways that are otherwise restricted. When the shortage ends, that pathway closes — though the rest of the 503A and 503B rules still apply either way.

When did compounding these drugs actually become illegal?

The deadlines differ by drug and by facility type — the single most-confused fact in this story. For tirzepatide, the enforcement window closed February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities. For semaglutide, it closed April 22, 2025 for 503A and May 22, 2025 for 503B. After those dates, the shortage exception no longer shielded compounders.

Source: FDA, “FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize.” Verified July 2, 2026.

The tirzepatide dates deserve a footnote, because you will see both “October 2024” and “December 2024” in the wild and both are right for different milestones. The FDA first declared the tirzepatide shortage resolved on October 2, 2024. After the compounding industry sued, the decision went back to the agency for reevaluation, and the FDA re-affirmed the resolution on December 19, 2024, this time with the wind-down deadlines above. Semaglutide came off the shortage list on February 21, 2025.

Did compounders fight back? Outsourcing Facilities Association v. FDA

Yes — the compounding industry’s trade group sued the FDA twice, and lost the merits both times at the district court. The Outsourcing Facilities Association challenged the tirzepatide determination (case 4:24-cv-00953) and the semaglutide determination (case 4:25-cv-00174), both in the Northern District of Texas before Judge Mark Pittman. The court denied preliminary injunctions in each, then ruled for the FDA on the merits in the tirzepatide case; both matters are now on appeal at the Fifth Circuit.

Source: federal court records, N.D. Tex.; Foley & Lardner, Buchanan Ingersoll, McDermott, and ArentFox Schiff reporting; FDA compounder-policy page. As of most recent reporting (mid-2026), both appeals were pending at the Fifth Circuit. Verified by The RX Index, July 2, 2026.

The practical upshot, as the court and the FDA both framed it: because tirzepatide and semaglutide are no longer “in shortage,” compounders cannot lean on the shortage exception to make copies. The appeals could still change the picture, which is one reason this tracker carries a verification date.

What is the 503B “bulks list,” and is the door closing for good?

On April 30, 2026, the FDA proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the list that decides which raw ingredients outsourcing facilities may compound from. If finalized, it would close the bulks-list pathway for large-scale compounding of these drugs. The public comment period (Federal Register docket FDA-2018-N-3240) was extended on June 26, 2026 to July 30, 2026, and a final determination was still pending as of July 2, 2026.

Here is the plumbing, because it is the crux of the endgame. A 503B facility can compound from a bulk drug substance only if (a) that substance is on the FDA’s 503B bulks list, or (b) the finished drug is on the shortage list at the time. The shortages are over, so door (b) is shut for now. The April 30 proposal would shut door (a) too, by finding there is “no clinical need” for outsourcing facilities to compound these three GLP-1s from bulk ingredient. The FDA was explicit that neither cost nor convenience counts as clinical need.

What about retatrutide, cagrilintide, and “research-use” peptides?

Retatrutide and cagrilintide cannot be used in compounding under federal law — they are not components of any FDA-approved drug and have not been found safe and effective for anything — and the FDA has started warning the companies marketing them anyway. This is the frontier of the crackdown: as the semaglutide and tirzepatide doors close, some sellers have pivoted to newer, still-investigational compounds, or to products labeled “for research purposes” and “not for human consumption” while being sold to consumers with dosing instructions.

According to ArentFox Schiff, the agency issued a distinct round of letters in April 2026 aimed at exactly this — “research use only” products and unapproved single, dual, and triple agonists. One letter in our tracker, GLP-1 Solution, named retatrutide alongside semaglutide and tirzepatide, which is why we coded it category 6. Expect this bucket to grow; it is the natural next move for anyone trying to stay an ingredient ahead of the rules.

Are drugmakers suing too? Novo Nordisk and Eli Lilly

Yes — alongside the FDA’s administrative enforcement, the two brand-name manufacturers have run their own litigation campaigns, and courts have generally sided with them. According to Novo Nordisk’s own statements, by mid-2025 the company had filed more than 130 lawsuits across roughly 40 states against telehealth companies and compounding pharmacies over compounded semaglutide; Eli Lilly has filed dozens more against med spas, clinics, and telehealth firms, at one point using a “corporate practice of medicine” theory against platforms including Mochi Health and Fella Health.

Treat these counts as attributed, not audited — there is no single public court census of GLP-1 compounding suits, so the figures come from the manufacturers’ releases and from reporting, and we have labeled them that way. The pushback runs both directions: at least one compounder, Strive Compounding Pharmacy, has countersued Lilly and Novo on antitrust grounds, arguing the drugmakers are choking off the pharmacies that could fill personalized prescriptions. The editorial read, drawn from the rulings rather than any one company’s spin: so far the legal system has mostly aligned with the manufacturers and the FDA, which is why continued compounding of copies carries real exposure.

Sources: Novo Nordisk press release (the 130-lawsuit / 40-state figure); STAT News and Buchanan Ingersoll (Eli Lilly’s telehealth suits); reporting on Strive Compounding Pharmacy’s antitrust complaint. Figures are company statements or reporting, not an independent court count.

How we built this tracker

We compiled this from primary records and coded it by hand. We read the FDA’s press releases and its two compounding-focused webpages (the telehealth guidance and the GLP-1 concerns page), opened and read the individual warning letters cited here on fda.gov, pulled the shortage and enforcement-discretion dates from the FDA compounder-policy page, confirmed the litigation from the federal court record, checked the 503B bulks-list status against the Federal Register docket, and cross-checked the warning-letter counts against reporting from Wilson Sonsini, Sheppard Mullin, McDermott, ArentFox Schiff, and Endpoints News.

Each warning-letter row lists the company, MARCS-CMS reference number, letter date, the drugs named, and a link to the letter on fda.gov, and is coded against the FDA’s own list of prohibited claims based on our reading of that letter’s stated violations. We give the source for every number; where a count comes from legal or trade reporting or a company statement rather than a single FDA table, we say so. We did not publish any warning-letter row we had not read in full, and we treat the FDA warning-letter database (searchable by “telehealth”) as the authoritative complete index. We update the “Last verified” date whenever we re-check the sources.

What this tracker does — and doesn’t — prove

It proves what the FDA and the courts have publicly done and alleged. It does not prove that any named company broke the law, harmed a patient, or is still non-compliant today. A warning letter is the FDA’s statement of concern and an invitation to respond — the agency itself notes that the matters in a letter may change after it interacts with the recipient, and that any letter is not an all-inclusive list of violations. Several of the companies here may have since corrected or removed the claims at issue.

The other honest limits: the adverse-event totals are reports, not confirmed causal events, and are underreported by the FDA’s own admission. The manufacturer-lawsuit counts are attributed estimates, not a court census. This tracker covers public federal action and the two headline OFA cases; it does not catalog every state-board action, every private cease-and-desist letter (most are never published), or matters under seal. And the 503B bulks-list exclusion is, as of this writing, proposed — the comment period runs through July 30, 2026, and no final rule has issued. None of this is legal or medical advice; for a specific situation, read the FDA’s pages directly and talk to qualified counsel or a clinician.

How to cite this page

Primary sources

• FDA press release “FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s” (March 3, 2026).
• FDA “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” (updated June 15, 2026).
• FDA “FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs” (updated June 15, 2026).
• FDA “FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize” (compounder-policy page with enforcement-discretion deadlines).
• FDA press release “FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List” (April 30, 2026).
• Federal Register Docket FDA-2018-N-3240, notice 2026-08552 (May 1, 2026); extension FR 2026-12937 (June 26, 2026). Comment period through July 30, 2026.
• FDA warning-letter database fda.gov/safety/warning-letters — search “telehealth” for the full set of GLP-1 telehealth letters.
• Court docket (N.D. Tex.) Outsourcing Facilities Association v. FDA, 4:24-cv-00953 (tirzepatide) and 4:25-cv-00174 (semaglutide), before Judge Mark Pittman.
• Wilson Sonsini Analysis of the September 2025 warning-letter wave and count methodology.
• Sheppard Mullin Reporting on the June 2026 wave (25 letters).
• Endpoints News Reporting on the June 2026 wave and timeline.
• Foley & Lardner Analysis of the tirzepatide litigation and shortage-list timeline.
• Buchanan Ingersoll; McDermott Will & Emery Analysis of the OFA v. FDA summary-judgment ruling (tirzepatide) and Eli Lilly litigation.
• ArentFox Schiff Reporting on the April 2026 “research use only” and unapproved-agonist enforcement wave.

Frequently asked questions